number four is google, number five is celgene. >> hmm. okay.hevron indeed that is a great -- that stock has been red-hot. they conserve that i capital. celgene, a summit based boy tech. alphabet, we know them as tech. apple is tech. schlumberger and chevron that's oil and office service. we will keefe shen ron, celgene and keep apple. this is very tough. i can't -- i'm going to let alphabet stand -- i have to. i have to. search and hardware, it's okay, youg you -- i love schlumberger, but we have to stay diverse fitted. what we're going to add here -- let's do the 3.5 yielding dow chemical. let's stay consistent. tom in georgia, tom? >> caller: yes. >> tom. >> caller: yes, sir. >> you're up. >> caller: all right. i'm asking -- thank you for having me. >> of course. >> caller: i'm interested in knowing your opinion on apple, starbucks, bowen, disney and facebook. >> okay. starbucks reports on the 21st i'm looking for an okay quarter. the sometimes the stock trades erratically. disney is finally getting its due. boeing fantastic. apple and facebo

we're talking about celgene, amgen, they actually look like opportunities from here. i think the simple way to make this play, look out to june, and buy the 300, 320 call spread, around 5 bucks. just about 1.5%. give or take. to take a bullish bet that will take you through the june expiration. it will capture a little bit of what's going on next week, and over the next couple of months. there was so much bad news baked into the space, it seems like you would be better poised for an upside move here. >> once it goes up to the downward trend line, 5% or 6%, what happens at that point? >> well, so, you're very kind to suggest that it's going to make it. let's hope so. >> well, let's pretend that -- >> if the trades work out, everyone's happy, then what. in principle when you return to the level, you find difficulty. it's not so much the management off the lows that you've gotten back to a level where people have been hurt and people return to them. it's really not so much upside. it's whether they can still on a relative basis outperform the s&p. >> i want to ask you, w

now celgene, host of very exciting new products in the pipeline.rodin didn't spot anything compelling on the chart. she went to a 30 minute chart where each tick is half an hour of trading. she sees a nice bullish pattern and the ratio suggests it could climb to 105, 107 or 114. that would be a big move. not all the charts are looking good. consider the daily pictograph and the action in gilead. given that the stock bottomed on february 2 and it is already rebounded from 82 to 95, big missouri. she thinks we missed the boat. she says it is legitimate to buy into weakness, she favors the other three over this one. you're getting in closer to the ground floor for the rallies. let me give you the bottom line here. the chart as interpreted by carol brodin said it is safe to come out and buy biotechses again. she likes biogen, re generon and celgene and you could get pull backs as long as the democratic primary continues and hillary clinton, the presumptive nominee feels the need to protect her left flank by bashing high drug prices and the companies th

then celgene. that's expected to move higher or lower. and gilead sciences.tock expected to move 4% in either direction. the move is just higher than that. this could represent a shift. >> and carter thinks that biotech could be setting up for a major breakout. what are you looking for? >> catch up with the s&p 500. this is a laggard group. recently, they're outperforming. let's take it back to the lows of 2011, when we had the u.s. debt downgrade. one of the biggest winners of all-time. what we have is the following. it's down 160 bucks. that's back from 317. you can look at it as a 50% retracement. and we've come to life vigorously off of the lows. here's the spread that exists. there's the bounce. and here, still, the opportunity as the s&p 500 has been going like that, more performance out of the biotech. we think this will continue to converge. we play ibb on the long side outright or paired against the s&p 500. how can you draw the lines? you can draw them this way, if you're negative, which it's a head and shoulders top. guess what. that played out. we

you take it over to a celgene is trading about one times that.asonable price. but the question, it goes back to what the guys were just talking about, are you going to see a hiccup in a regulatory environment, a political environment, that could take down everybody with it. i think there's a lot of value traps out there. you have to be careful choosing stocks at a relative growth. >> interesting that you referred to her as mel, when it's actually meg. >> oh, excuse me. >> what i think is really going on here is i think you're starting to get separation from the guys. amgen, those numbers beat the street. growing 10%. giving you 450 to 500 basis points at a time when the stock's been sideways. some of these guys are actually worth paying a premium for and some are slipg to the down side. >> if you want to be 234 biotech, you have to say, now gilead is forced with their balance sheet, which is pristine, you can say what you want about their business, their balance sheet is unbelievable. they'll have to go out fishing for somebody. if anybody can ma

make a decision on how we talk about the biotech, because there is biotech with the big name of the celgenesnd the biogens, and the tech like this half a billion market cap, and the volatility that jon is talking about right now, and these are different. you are not talking about the earnings, but talking about getting a stock that you are looking at, and phase three, and you are trying to get a stock into the marketplace or excuse me, a drug into the marketplace, and that is a difference. people have the understand the difference of some of the company, and yes, everybody has face street in the pipeline, but it is the companies that don't have drugs on the market or very little in terms of earnings like this company or those who have all kinds of different drugs, but trying to develop more, and that the huge difference between. >> to me, the bigger story or the lesson especially with the biotech and pharma is not to vote with the harriet, and when you see the advisory panel meeting, it was supposed to be 10 or 11 hours and filled with people who have family members suffering from the diseas

. >> a question of whether the company would go shopping for the likes of celgene and valeant now that off the table. we thought we'd plate allergen dating game. contestant number one, peter najarian, he just prefers long walks in the option pit. bachelor number two, brian kelly loves mass chaos, financial destruction and bitcoin and he just cashed out of his 401(k) so, ladies, dinner is on him and bachelor number three is founder of riskreversal.com and dan nathan knows how to straddle a trade and our fourth bachelor is guy adam, many ladies call him the godfather because he's known to make an offer you can't refuse. pete, kick it off with you. >> i'm going with biogen. looking for growth, talk about growth pharma, that's why he's looking at this particular name. the ms franchise and the fact that they are in the hemophilia, huge growth there as well, look the at the ref niece and earnings growth, the real key, they are very bottom. alzheimer's. they have a drug in late stage for alzheimer's, could be very huge. >> work on your penmanship. brian kelly, who should allergen buy? >> bost

a lot of the biotechs, some of them hit highs this week, i think those are dangerous, the big one celgenegeneron i think are still good. regeneron is a buy but you have to be willing to accept the fact there are some price risks. that, ladies and gentlemen, is the conclusion of the lightning round. [ buzzer ] >> announcer: the lightning round is sponsored by td ameritrade. >>> good evening, jim, thaw for taking my call. after taking a tour of again necessary brewery at the end of the tour i found out that they were owned by diagio. >> i went to that same guinness and i happen to have a diploma for pouring and it's also my wife's screen safer. she got -- she had magna cum laude pour. that was the first course i have taken since harvard and it was much harder. >> how about this check that cbs is priegt for march madness, extension for eight years. >> until 2032. >> the joke was are we going to be watching it on vr, is it going to look like you're court side from home? >> you will just be a box watching it. >> i'm a bot? >> you will be marching around with those goggles on. >> yeah, these ar

near the top is like a celgene, expaidia. that's become being more of aing point. >> a lot of what i regards ak the let's go on but we're going to keep a closer eye on that. it's an issue and it does get to the relevance of the actual numbers we are getting or at least working off of. >> level playing field. you have some companies that are reporting thanks they're doing. we're going to get caterpillar. it has always been like here, open kim own owe. they could use some kind of -- >> kind of a bit of an overload here. i will point out that network, communications and cloud service now, these things are still on fire. hark back to yesterday, intel, where i still believe that they're the two companies and one company is involved with the internet of things and involved with networking. they are so strong, it's hard to believe that google could be disappointing. another team, currency -- they're still acting as if the dollar is very strong. that sets up for a good second half for a lot of these companies. networking, if you gont